Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium. What is daily practice in HCC?
Van Vlierberghe H, Colle I, Henrion J, Michielsen P, Delwaide J, Reynaert H, Borbath I, Martinet JP, Sprengers D, Brenard R; Belgian Assocation for the Study of the Liver steering committee. Van Vlierberghe H, et al. Among authors: borbath i. Acta Gastroenterol Belg. 2005 Oct-Dec;68(4):403-11. Acta Gastroenterol Belg. 2005. PMID: 16432990
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.
Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, Tiensuu Janson E, Ramage J; Antibes Consensus Conference participants. Hicks RJ, et al. Among authors: borbath i. Neuroendocrinology. 2017;105(3):295-309. doi: 10.1159/000475526. Epub 2017 Apr 13. Neuroendocrinology. 2017. PMID: 28402980 No abstract available.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Santoro A, et al. Among authors: borbath i. Lancet Oncol. 2013 Jan;14(1):55-63. doi: 10.1016/S1470-2045(12)70490-4. Epub 2012 Nov 20. Lancet Oncol. 2013. PMID: 23182627 Clinical Trial.
Significant impact of transient deterioration of renal function on dosimetry in PRRT.
Van Binnebeek S, Baete K, Terwinghe C, Vanbilloen B, Haustermans K, Mortelmans L, Borbath I, Van Cutsem E, Verslype C, Mottaghy FM, Verbruggen A, Deroose CM. Van Binnebeek S, et al. Among authors: borbath i. Ann Nucl Med. 2013 Jan;27(1):74-7. doi: 10.1007/s12149-012-0651-y. Epub 2012 Sep 9. Ann Nucl Med. 2013. PMID: 22961123
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Raymond E, et al. Among authors: borbath i. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. N Engl J Med. 2011. PMID: 21306237 Free article. Clinical Trial.
The role of surgery and transplantation in neuroendocrine tumours.
Roeyen G, Chapelle T, Borbath I, Delaunoit T, Demetter P, Demolin G, Hendlisz A, Pattyn P, Pauwels S, Peeters M, Van Cutsemo E, Van Hootegem P, Van Laethem JL, Verslype C, Ysebaert D. Roeyen G, et al. Among authors: borbath i. Acta Gastroenterol Belg. 2009 Jan-Mar;72(1):39-43. Acta Gastroenterol Belg. 2009. PMID: 19402370 Review.
Carcinoid heart disease--a hidden complication of neuroendocrine tumours.
Dero I, De Pauw M, Borbath I, Delaunoit T, Demetter P, Demolin G, Hendlisz A, Pattyn P, Pauwels S, Roeyen G, Van Cutsem E, Van Hootegem P, Van Laethem JL, Verslype C, Peeters M. Dero I, et al. Among authors: borbath i. Acta Gastroenterol Belg. 2009 Jan-Mar;72(1):34-8. Acta Gastroenterol Belg. 2009. PMID: 19402369 Review.
139 results